GlaxoSmithKline's board has limited the bonus paid to chief executive Sir Andrew Witty following the major corruption scandal involving the company in China last year. However the size of this pen ...
as the lobby group looks to rebuild its membership after a sexual misconduct scandal last year. Firms including FTSE 100 ...
Until recently, the pharmaceutical industry remained relatively insulated from the simmering trade war between China and the ...
GlaxoSmithKline has dismissed more than 100 staff in China as a result of its internal investigation into the corruption scandal for which it was fined £300m last year. The action is the biggest round ...
The Chinese bribery scandal is starting to hurt big pharma ... Of course, there is GlaxoSmithKline, which was the initial focus of the Chinese government probe. The others registering pain ...
CEO Sir Andrew Witty reduced his bonus by £245,000 ($368,140) in response to the scandal. According to Mick Cooper, an analyst at Edison, the implications for GSK were significant and the company ...
The scandal led to an exodus of large corporate ... including Unilever and GSK. Sign up to the Front Page newsletter for free ...
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...
The scandal led to an exodus of large corporate members that battered the group’s finances, although it received a vote of confidence from its remaining members at an extraordinary general ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback